DNA Synthesis Market Overview

The DNA Synthesis Market is positioned for a period of explosive growth from 2025 to 2033, fueled by the rapid advancements in synthetic biology, declining costs of synthesis, and its expanding applications in personalized medicine and biopharmaceuticals. The market is projected to be valued at approximately USD 7.9 billion in 2025 and is forecasted to reach nearly USD 21.9 billion by 2033, exhibiting a remarkable compound annual growth rate (CAGR) of 14.1% during this period.

DNA synthesis, the process of chemically creating DNA sequences in a laboratory, is a foundational technology for modern biotechnology. It encompasses both short fragments (oligonucleotides) and long stretches (genes and genomes). The market growth is primarily driven by the burgeoning field of synthetic biology, which uses synthesized DNA to engineer biological systems for novel applications. Key drivers include the development of DNA-based therapeutics (e.g., mRNA vaccines, CRISPR gene editing), the demand for customized genes for protein engineering and metabolic pathway construction, and the increasing adoption of synthetic DNA in diagnostics (e.g., probes, primers).

Technological innovations such as enzymatic DNA synthesis, which promise faster, cheaper, and more accurate production, and the push towards high-throughput, automated synthesis platforms are key market enablers. North America is the dominant regional market due to a high concentration of biotech firms and significant R&D investment, while the Asia-Pacific region is expected to witness the fastest growth, driven by expanding life science research capabilities and government initiatives.

DNA Synthesis Market Drivers and Opportunities

The Rise of Synthetic Biology and Biopharmaceuticals is a Primary Growth Engine

Synthetic biology is revolutionizing industries by enabling the design and construction of new biological parts and systems. DNA synthesis is the literal "code" that brings these designs to life. This directly translates into massive demand for synthesized genes used in the production of engineered cell therapies, novel vaccines (like mRNA), industrial enzymes, and sustainable biomaterials. The success of mRNA vaccine platforms during the COVID-19 pandemic has permanently established the critical role of rapid, large-scale oligonucleotide synthesis in responding to global health crises and developing new therapeutic modalities.

The pipeline for DNA/RNA-based therapeutics has exploded. From mRNA and CRISPR to cell therapies, each modality requires custom-designed, high-fidelity DNA sequences. The shift from small molecules to large biologics and now to informational drugs (DNA/RNA) means the drug substance is literally a synthesized nucleic acid, creating a non-negotiable, high-value demand.

Advancements in Therapeutic and Diagnostic Applications Create Sustained Demand

The application of synthesized DNA in therapeutics is expanding beyond traditional approaches. It is now indispensable for CRISPR-based gene editing (requiring guide RNAs and donor DNA templates), antibody drug discovery, and the development of DNA/RNA-based drugs. In diagnostics, customized oligonucleotides are essential for PCR tests, next-generation sequencing (NGS), and a new generation of molecular diagnostics. The trend towards personalized medicine, which often requires patient-specific probes or primers, further tailors this demand and pushes for more agile and responsive synthesis services.

Technological Shifts and Automation Present Significant Opportunities

The market is on the cusp of a technological transformation with the commercialization of enzymatic DNA synthesis as a potential successor to the traditional phosphoramidite method. Enzymatic synthesis offers advantages such as longer fragment synthesis, reduced use of hazardous chemicals, and the potential for massively parallel production, which could drastically lower costs. This innovation, coupled with the integration of AI for sequence optimization and the expansion of automated, cloud-connected synthesis platforms, presents significant opportunities for companies to capture market share. The emergence of "DNA synthesis as a service" from specialized CROs is also making the technology accessible to a broader range of end-users, further expanding the market.

DNA Synthesis Market Scope

DNA Synthesis Market Report Segmentation Analysis

The global DNA synthesis market industry analysis is segmented by Product, by Application, by End-User, and by Region.

The Oligonucleotide Synthesis segment is anticipated to command a significant share in the global DNA Synthesis Market during the forecast period.

Based on product, the market is divided into Oligonucleotide Synthesis and Gene Synthesis. The Oligonucleotide Synthesis segment currently holds the largest share due to its ubiquitous use in research, PCR, diagnostics, and as starting materials for gene synthesis. The high-volume demand for primers, probes, and antisense oligonucleotides for therapeutic applications solidifies its dominance. However, the Gene Synthesis segment is expected to grow at a faster CAGR, driven by the increasing complexity of synthetic biology projects requiring long, accurate DNA sequences.

The Therapeutics segment dominated the market in 2025 and is projected to grow at the highest CAGR during the forecast period.

Based on application, the market is segmented into Therapeutics, Diagnostics, Research & Development, and Others. The Therapeutics segment holds the largest share and is the fastest-growing. This is a direct result of the clinical and commercial success of oligonucleotide-based drugs, mRNA vaccines, and the extensive use of synthesized DNA in the research and development of advanced cell and gene therapies. The high value of these therapeutic applications contributes significantly to the segment's revenue.

The dominance of the Therapeutics segment is underpinned by the paradigm shift in medicine towards targeting diseases at the genetic level. Synthesized DNA and RNA are no longer just research tools but have become the active pharmaceutical ingredients (APIs) in a new class of drugs. The scalability of synthesis manufacturing to meet clinical and commercial demand, coupled with strong regulatory pathways for these novel modalities, has created a robust and high-growth market. The pipeline of DNA/RNA-based therapeutics in clinical trials ensures that this demand will continue to accelerate.

The Pharmaceutical & Biotechnology Companies segment is expected to hold the largest market share in 2025.

By end-user, the market is divided into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research & Manufacturing Organizations (CROs/CMOs). The Pharmaceutical & Biotechnology Companies segment is the largest end-user. This is due to their substantial internal R&D programs focused on novel therapeutics and their need for large quantities of high-quality DNA for discovery and development processes.

The following segments are part of an in-depth analysis of the global DNA Synthesis Market:

DNA Synthesis Market Share Analysis by Region

The North America region is anticipated to hold the largest portion of the DNA Synthesis Market globally throughout the forecast period.

North America is the leading segment, holding a dominant share. This leadership is anchored by the presence of a world-leading biopharmaceutical industry, top-tier research universities, and significant government funding from agencies like the NIH. The region is also a hotbed for synthetic biology startups and venture capital investment, creating a vibrant ecosystem for innovation and adoption of DNA synthesis technologies.

The dominance of North America, particularly the United States, is a direct reflection of its mature and risk-capital-rich biotechnology landscape. The high concentration of companies developing advanced therapeutics (mRNA, CRISPR, cell therapy) that are entirely dependent on synthesized DNA creates a core, high-value market. Furthermore, the regulatory clarity provided by the FDA for these new modalities encourages investment and commercial development. The presence of major DNA synthesis service providers and technology developers within the region creates a synergistic environment that reinforces its leadership position.

DNA Synthesis Market Competition Landscape Analysis

The global DNA synthesis market is characterized by a mix of large, established life science tool companies and specialized, agile synthetic biology firms. Competition is intense and based on factors such as synthesis speed, accuracy, length capabilities, price, and the robustness of e-commerce and ordering platforms. Key strategies include heavy investment in R&D to pioneer next-generation synthesis technologies (like enzymatic synthesis), vertical integration to offer end-to-end services from gene design to validation, and strategic partnerships with therapeutic developers. The market is also seeing a trend of consolidation as larger players acquire specialized firms to bolster their technological portfolios and service capabilities.

Global DNA Synthesis Market Recent Developments News:

• In February 2025, Twist Bioscience Corporation announced a partnership with a major pharmaceutical company to supply synthetic genes for its pipeline of cell therapies. This partnership validates Twist's leadership in high-quality, high-throughput gene synthesis. By securing a major pharmaceutical partner for cell therapies, Twist ensures a long-term revenue stream and deepens its integration into the therapeutic development pipeline. Cell therapies represent one of the most advanced and valuable applications of synthetic biology, requiring complex, customized genetic constructs.
• In December 2024, Danaher Corporation acquired a startup specializing in enzymatic DNA synthesis to enhance its portfolio of genomics solutions. Danaher's acquisition is a strategic move to future-proof its genomics portfolio, currently led by its subsidiary IDT. Enzymatic DNA synthesis is an emerging technology that promises to be greener, faster, and more accurate than the traditional chemical method, especially for long DNA fragments.
• In October 2024, Codex DNA launched a new automated benchtop system for high-throughput synthesis of long DNA fragments. The launch of an automated benchtop system addresses a key market need for speed and accessibility in synthetic biology. By automating the complex process of synthesizing long DNA fragments, Codex DNA is enabling researchers to rapidly prototype genetic designs in their own labs, drastically reducing wait times associated with outsourcing.
• In August 2024, Thermo Fisher Scientific Inc. expanded its GMP-grade oligonucleotide manufacturing capacity to meet the growing demand for therapeutic APIs. This expansion directly targets the rapidly growing market for oligonucleotide-based therapeutics, including mRNA vaccines, ASOs, and siRNA drugs. GMP (Good Manufacturing Practice) grade is mandatory for any substance used as a human drug. 

The Global DNA Synthesis Market Is Dominated by a Few Large Companies, such as

●        Twist Bioscience Corporation

●        Danaher Corporation

●        Thermo Fisher Scientific Inc.

●        Merck KGaA

●        Eurofins Scientific

●        Brooks Automation

●        Codex DNA 

●        LGC Biosearch Technologies

●        ATUM

●        Synbio Technologies

●        Bioneer Corporation

●        Bio Basic Inc.

●        GENSCRIPT Biotech Corporation

●        Kaneka Corporation (Kaneka Eurogentec S.A.)

●        TriLink BioTechnologies 

●        Other Players